Get the Stockscreener App
0.697
0.09%
0.0006
After Hours:
.71
0.013
+1.87%
Ovid Therapeutics Inc Stock (OVID) Latest News
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart
Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Ovid Therapeutics (NASDAQ:OVID) Upgraded by Oppenheimer to Outperform Rating - MarketBeat
Oppenheimer raises Ovid stock rating, sets $4 price target - MSN
Ovid Therapeutics stock hits 52-week low at $0.68 amid downturn - MSN
Ovid upgraded to outperform by Oppenheimer, OV329 cited - MSN
Ovid therapeutics president and COO acquires $4,971 in stock - MSN
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’ - Yahoo Finance
Oppenheimer Upgrades Ovid Therapeutics to Outperform From Perform, $4 Price Target - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Barclays PLC Acquires 63,702 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Insider Activity Raises Eyebrows! Key Moves at Ovid Therapeutics! - Jomfruland.net
Ovid Therapeutics Insider Ups Holding During Year - Yahoo Finance
Short Interest in Ovid Therapeutics Inc. (NASDAQ:OVID) Decreases By 27.0% - MarketBeat
Jane Street Group LLC Has $45,000 Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - Defense World
Ovid’s Gameplan: Flicking The Master Switch In Neurology - News & Insights
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Geode Capital Management LLC Acquires 14,816 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
TG Therapeutics (NASDAQ:TGTX) Raised to Hold at StockNews.com - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Acquired by Barclays PLC - Defense World
Fragile X Syndrome Market Expected to rise, 2034 | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia - Barchart
Ovid Therapeutics Inc (NASDAQ: OVID) Drops -2.44 Percent In Recent Trading, What Questions Do You Have? - Stocks Register
Ovid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short Interest - MarketBeat
Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935 - Reuters
Fmr LLC Acquires 47,723 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - MarketBeat
Verition Fund Management LLC Makes New Investment in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
3 US Penny Stocks With Market Caps Over $20M - Simply Wall St
Convergent Therapeutics Appoints Barbara Duncan to Board of Directors - citybiz
HC Wainwright Has Bullish Estimate for OVID FY2024 Earnings - MarketBeat
HC Wainwright Has Strong Forecast for OVID FY2024 Earnings - Defense World
KCC2 activation nears inflection point - BioCentury
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Ovid Therapeutics to Present Multiple Posters Supporting - GlobeNewswire
Ovid Therapeutics Unveils Breakthrough Epilepsy Treatment Data at Major Conference | OVID Stock News - StockTitan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus PT from Analysts - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Analysts - MarketBeat
B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Equities Analysts Offer Predictions for OVID FY2024 Earnings - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):